ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Why are we doing this research?

This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features.

Who can participate?

Histologically confirmed diagnosis of 1 of the following:  

  • Neuroblastoma
  • Rhabdomyosarcoma
  • Wilms tumor
  • Retinoblastoma
  • Adrenocortical carcinoma
  • Carcinoid tumor
  • Relapsed or refractory disease
  • Measurable or evaluable disease
  • No known curative therapy or therapy proven to prolong survival with an acceptable quality of life
  • No known pulmonary tumors or metastases > 5 cm, as evaluated by chest CT scan
  • No clinically significant pulmonary and/or pericardial effusions (≤grade 3), as evaluated by ECHO
  • No primary CNS tumors or known metastatic CNS disease involvement


  • Cancer - Kidney Tumors


  • Female
  • Male


Cincinnati Children’s Hospital Medical Center
Cancer and Blood Diseases Institute
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799